Atria Wealth Solutions Inc. Has $409,000 Stock Holdings in Humana Inc. (NYSE:HUM)

Atria Wealth Solutions Inc. lifted its position in shares of Humana Inc. (NYSE:HUM) by 21.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,610 shares of the insurance provider’s stock after purchasing an additional 281 shares during the period. Atria Wealth Solutions Inc.’s holdings in Humana were worth $409,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in HUM. AMF Tjanstepension AB increased its holdings in Humana by 166.8% in the third quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock valued at $12,686,000 after purchasing an additional 25,041 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Humana by 12.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,090 shares of the insurance provider’s stock valued at $1,295,000 after buying an additional 461 shares during the last quarter. AustralianSuper Pty Ltd increased its stake in shares of Humana by 35.2% in the third quarter. AustralianSuper Pty Ltd now owns 2,495 shares of the insurance provider’s stock valued at $790,000 after buying an additional 650 shares during the period. Creative Financial Designs Inc. ADV raised its position in shares of Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares during the last quarter. Finally, CacheTech Inc. lifted its stake in shares of Humana by 5.7% in the third quarter. CacheTech Inc. now owns 7,818 shares of the insurance provider’s stock worth $2,476,000 after acquiring an additional 422 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM opened at $261.49 on Friday. The stock has a 50-day moving average price of $270.64 and a 200-day moving average price of $287.87. The company has a market cap of $31.55 billion, a PE ratio of 26.28, a price-to-earnings-growth ratio of 2.05 and a beta of 0.56. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.35%. Humana’s payout ratio is 35.58%.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.32% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. StockNews.com raised shares of Humana from a “hold” rating to a “buy” rating in a research report on Tuesday. Wells Fargo & Company decreased their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. JPMorgan Chase & Co. dropped their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Piper Sandler increased their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Finally, Truist Financial lifted their price objective on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Nineteen equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.